Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Gossamer Bio Announces GB004 Clinical Trial Data Presentations at 2021 Virtual Congress of the European Crohn’s and Colitis Organisation By: Gossamer Bio, Inc. via Business Wire July 07, 2021 at 07:01 AM EDT Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, today announced that it will present data related to GB004 at the 2021 Virtual Congress of the European Crohn’s and Colitis Organisation (ECCO), to be held virtually from July 2-3 and 8-10. On July 8, William Sandborn, M.D., will present a digital oral presentation, which will include target engagement and pharmacodynamic biomarker data from the completed GB004 Phase 1b clinical trial in patients with mild-to-moderate ulcerative colitis. Details for presentations related to GB004, an oral, gut-target HIF-1α stabilizer, are as follows: Digital Oral Presentation Title: Target Engagement and Pharmacodynamic Biomarker Analysis following Treatment with the Oral Gut-Targeted HIF-1α Stabilizer GB004 in a Phase 1b Trial in Active Ulcerative Colitis Presenting Author: William Sandborn, M.D. Date: Thursday, July 8, 2021 Session Title: DOP Session 1 - Molecular Profiling Presentation Code: DOP05 Presentation Time: 8:10 – 8:15 a.m. PDT / 11:10 – 11:15 a.m. EDT / 5:10 – 5:15 p.m. CEST ePoster Title: GB004 Drives Protective Effects on Immune Cells and Epithelial Cells Using Human Ex Vivo Monolayer and Co-Culture Systems Poster Code: P059 The presentation and poster can be accessed on the ECCO website. The presentation and poster will also be made available in the “Posters and Publications” section of the Gossamer Bio website at gossamerbio.com, after the conclusion of the Virtual Congress. About Gossamer Bio Gossamer Bio is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology. Its goal is to be an industry leader in each of these therapeutic areas and to enhance and extend the lives of patients suffering from such diseases. View source version on businesswire.com: https://www.businesswire.com/news/home/20210707005256/en/Contacts For Investors and Media: Bryan Giraudo, Chief Financial Officer Gossamer Bio Investor Relations ir@gossamerbio.com Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
Gossamer Bio Announces GB004 Clinical Trial Data Presentations at 2021 Virtual Congress of the European Crohn’s and Colitis Organisation By: Gossamer Bio, Inc. via Business Wire July 07, 2021 at 07:01 AM EDT Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, today announced that it will present data related to GB004 at the 2021 Virtual Congress of the European Crohn’s and Colitis Organisation (ECCO), to be held virtually from July 2-3 and 8-10. On July 8, William Sandborn, M.D., will present a digital oral presentation, which will include target engagement and pharmacodynamic biomarker data from the completed GB004 Phase 1b clinical trial in patients with mild-to-moderate ulcerative colitis. Details for presentations related to GB004, an oral, gut-target HIF-1α stabilizer, are as follows: Digital Oral Presentation Title: Target Engagement and Pharmacodynamic Biomarker Analysis following Treatment with the Oral Gut-Targeted HIF-1α Stabilizer GB004 in a Phase 1b Trial in Active Ulcerative Colitis Presenting Author: William Sandborn, M.D. Date: Thursday, July 8, 2021 Session Title: DOP Session 1 - Molecular Profiling Presentation Code: DOP05 Presentation Time: 8:10 – 8:15 a.m. PDT / 11:10 – 11:15 a.m. EDT / 5:10 – 5:15 p.m. CEST ePoster Title: GB004 Drives Protective Effects on Immune Cells and Epithelial Cells Using Human Ex Vivo Monolayer and Co-Culture Systems Poster Code: P059 The presentation and poster can be accessed on the ECCO website. The presentation and poster will also be made available in the “Posters and Publications” section of the Gossamer Bio website at gossamerbio.com, after the conclusion of the Virtual Congress. About Gossamer Bio Gossamer Bio is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology. Its goal is to be an industry leader in each of these therapeutic areas and to enhance and extend the lives of patients suffering from such diseases. View source version on businesswire.com: https://www.businesswire.com/news/home/20210707005256/en/Contacts For Investors and Media: Bryan Giraudo, Chief Financial Officer Gossamer Bio Investor Relations ir@gossamerbio.com
Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, today announced that it will present data related to GB004 at the 2021 Virtual Congress of the European Crohn’s and Colitis Organisation (ECCO), to be held virtually from July 2-3 and 8-10. On July 8, William Sandborn, M.D., will present a digital oral presentation, which will include target engagement and pharmacodynamic biomarker data from the completed GB004 Phase 1b clinical trial in patients with mild-to-moderate ulcerative colitis. Details for presentations related to GB004, an oral, gut-target HIF-1α stabilizer, are as follows: Digital Oral Presentation Title: Target Engagement and Pharmacodynamic Biomarker Analysis following Treatment with the Oral Gut-Targeted HIF-1α Stabilizer GB004 in a Phase 1b Trial in Active Ulcerative Colitis Presenting Author: William Sandborn, M.D. Date: Thursday, July 8, 2021 Session Title: DOP Session 1 - Molecular Profiling Presentation Code: DOP05 Presentation Time: 8:10 – 8:15 a.m. PDT / 11:10 – 11:15 a.m. EDT / 5:10 – 5:15 p.m. CEST ePoster Title: GB004 Drives Protective Effects on Immune Cells and Epithelial Cells Using Human Ex Vivo Monolayer and Co-Culture Systems Poster Code: P059 The presentation and poster can be accessed on the ECCO website. The presentation and poster will also be made available in the “Posters and Publications” section of the Gossamer Bio website at gossamerbio.com, after the conclusion of the Virtual Congress. About Gossamer Bio Gossamer Bio is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology. Its goal is to be an industry leader in each of these therapeutic areas and to enhance and extend the lives of patients suffering from such diseases. View source version on businesswire.com: https://www.businesswire.com/news/home/20210707005256/en/
For Investors and Media: Bryan Giraudo, Chief Financial Officer Gossamer Bio Investor Relations ir@gossamerbio.com